Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imidapril for cancer cachexia in non-small cell lung cancer (phase IIa)
2007-004340-67Phase 2Terminated
- Sponsor
- Ark Therapeutics
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and non-small cell lung cancer (NSCLC) comparing Imidapril with Placebo (2 arms). Primary endpoint: Rate of change in body cell mass. Started Mar 2008; status: terminated.
02
Drugs
imidapril
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004340-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004340-67.